Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Perrigo Company PLC    PRGO   IE00BGH1M568

PERRIGO COMPANY PLC

(PRGO)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/17/2019 06/18/2019 06/19/2019 06/20/2019 06/21/2019 Date
43.75(c) 43.87(c) 44.37(c) 43.48(c) 44.5(c) Last
975 877 843 353 1 529 502 1 944 401 1 851 813 Volume
+1.32% +0.27% +1.14% -2.01% +2.35% Change
More quotes
Financials (USD)
Sales 2019 4 718 M
EBIT 2019 799 M
Net income 2019 299 M
Debt 2019 2 563 M
Yield 2019 1,77%
Sales 2020 4 814 M
EBIT 2020 768 M
Net income 2020 377 M
Debt 2020 2 075 M
Yield 2020 1,84%
P/E ratio 2019 29,67
P/E ratio 2020 25,57
EV / Sales2019 1,83x
EV / Sales2020 1,69x
Capitalization 6 052 M
More Financials
Company
Perrigo Company PLC (Perrigo), formerly Perrigo Company Limited, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company's segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx) and Specialty Sciences.... 
Sector
Pharmaceuticals
Calendar
08/08Earnings Release
More about the company
Surperformance© ratings of Perrigo Company PLC
Trading Rating : Investor Rating :
More Ratings
Latest news on PERRIGO COMPANY PLC
06/21PERRIGO : Issues voluntary recall for parent's choice advantage infant formula m..
PU
05/30PERRIGO COMPANY PLC : Ex-dividend day for
FA
05/29SOL GEL TECHNOLOGIES : Announces Seventh Agreement for Generic Product Candidate..
AQ
05/28PERRIGO : Sol-Gel Technologies Announces Seventh Agreement for Generic Product C..
AQ
05/22Monteverde & Associates PC Launches Legal Inquiry Regarding the Acquisition
PR
05/22PERRIGO : Announces FDA Final Approval for AB Rated Generic Version of Voltaren ..
AQ
05/14PERRIGO CO PLC : Entry into a Material Definitive Agreement (form 8-K)
AQ
05/09PERRIGO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
05/09MARKET SNAPSHOT: S&P 500, Nasdaq End Lower For Fourth Day After Trump Claims ..
DJ
05/08PERRIGO CO PLC : Results of Operations and Financial Condition, Financial Statem..
AQ
More news
Analyst Recommendations on PERRIGO COMPANY PLC
More recommendations
Sector news : Pharmaceuticals - NEC
07:45aBRISTOL MYERS SQUIBB : to divest Celgene's psoriasis treatment in FTC clearance ..
RE
07:45aBRISTOL MYERS SQUIBB : to divest Celgene's psoriasis treatment in FTC clearance ..
RE
06/21European stocks pause after third week of gains
RE
06/21NOVARTIS : U.S. group says Novartis MS drug price out of line with benefit
RE
06/21GLOBAL MARKETS LIVE : Chevron Phillips, Nova, GSK, Slack…
More sector news : Pharmaceuticals - NEC
Chart PERRIGO COMPANY PLC
Duration : Period :
Perrigo Company PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PERRIGO COMPANY PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 51,7 $
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Murray S. Kessler President, Chief Executive Officer & Director
Rolf Allan Classon Chairman
Ronald Janish Executive VP-Global Operations and Supply Chain
Ron L. Winowiecki Chief Financial Officer
Thomas Farrington Chief Information Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
PERRIGO COMPANY PLC14.84%5 793
JOHNSON & JOHNSON10.10%348 981
PFIZER0.05%233 072
ROCHE HOLDING LTD.13.87%227 848
NOVARTIS21.31%220 893
MERCK AND COMPANY10.68%206 641